Clinical trials have become the most costly and time-intensive phase of drug development, accounting for 60 to 70 percent of total expenses. The process of bringing a new drug to market can span seven to fifteen years, with fewer than 12 percent of drugs entering human trials ultimately gaining approval. This creates a bottleneck that threatens both the profitability of the pharmaceutical industry and global healthcare innovation. The urgency for smarter, faster, and more efficient clinical trials has never been greater.
Erik Terjesen, Managing Director at Silicon Foundry, suggests that the key to resolving this issue is not in accelerating molecule discovery, but in reimagining drug testing methods. His focus is on assisting pharmaceutical leaders in partnering with AI-driven startups that are revolutionizing the clinical trial process, including virtual patient simulations, adaptive trial design, and real-time oversight.
While AI has been celebrated for its role in drug discovery, the true bottleneck lies in clinical trials. Recruitment, data collection, compliance, and patient retention often cause costly delays. AI can address these challenges by identifying ideal trial sites, predicting patient drop-off, and flagging data anomalies before they affect study validity.
A promising innovation is the digital twin—virtual patient models created from real-world data. These simulations mimic a patient’s physiology, genetics, and medical history, allowing researchers to test hypotheses without risking real patients. Digital twins can model drug interactions, predict side effects, and optimize dosing strategies before a trial begins. By running thousands of simulations, they can reduce the number of physical participants needed, shorten timelines, and lower costs.
AI is also transforming trial design and monitoring. Adaptive AI systems can analyze live data from ongoing studies, suggesting adjustments to enrollment criteria, dosage levels, or endpoints. This real-time adaptability can enhance patient safety and improve trial success rates by identifying responsive patients early.
However, AI integration in clinical trials faces challenges, such as fragmented medical data and regulatory hurdles. Data is often scattered across various entities, requiring massive coordination for integration. Regulatory bodies like the FDA are cautiously optimistic about AI, but models must demonstrate transparency and consistent performance to influence trial decisions.
